Kisspeptin-10: Evidence, Mechanism, Dosing & Legal Status

Kisspeptin-10 (KP-10; sequence YNWNSFGLRF-NH2, the C-terminal decapeptide of the KISS1-encoded metastin) is marketed and discussed as a libido, testosterone, and fertility peptide. Its biology is extraordinary and well proven; the leap to a consumer therapeutic is not. This monograph separates the two.1

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Kisspeptin-10 is an investigational substance not approved by the FDA for any indication; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Kisspeptin-10 and how does it work?

Kisspeptins are a family of C-terminally amidated RFamide peptides cleaved from a 145-amino-acid precursor encoded by the KISS1 gene, originally identified as a metastasis-suppressor. The precursor yields a 54-residue peptide (kisspeptin-54, or metastin) and shorter 14-, 13-, and 10-residue fragments, all sharing the identical C-terminal decapeptide YNWNSFGLRF-NH2.217 KP-10 is the minimal fully bioactive fragment and retains full agonist potency at the receptor, which is why it is so widely used in research; the C-terminal residues are critical to agonism at human KISS1R.11

Kisspeptins are the endogenous ligands for KISS1R (GPR54), a seven-transmembrane G-protein-coupled receptor on chromosome 19p13.3, identified as the kisspeptin receptor in 2001. KP-10 binds KISS1R with roughly nanomolar affinity; receptor activation engages Gq/11, then phospholipase C, then IP3 and DAG, releasing intracellular calcium and activating PKC, which depolarizes GnRH neurons.2 The physiological necessity of this pathway is definitive — the experiment of nature: loss-of-function mutations in KISS1R/GPR54 cause normosmic hypogonadotropic hypogonadism and failure of puberty, while activating mutations cause precocious puberty.2

The axis is strictly hierarchical and pulsatile: KISS1 neurons activate KISS1R on GnRH neurons, which release pulsatile GnRH into the hypophyseal portal system, prompting the pituitary to secrete LH and FSH and the gonads to produce sex steroids. Critically, kisspeptin acts upstream of GnRH, stimulating the axis at its physiological origin rather than bypassing it.1 In the human dose-response study, a 100-microgram GnRH bolus produced an LH peak (~89 IU/L) far exceeding any KP-10 response (about 21 IU/L at most), consistent with KP-10 acting one step upstream and being constrained by the capacity of the GnRH neurons themselves.1

The defining pharmacokinetic feature is an extremely short plasma half-life of about four minutes in humans (versus roughly 28 minutes for KP-54), due to rapid cleavage by plasma proteases and matrix metalloproteinases.10 Yet the downstream neuroendocrine effect — the LH rise — peaks at 30 to 40 minutes and persists one to two hours, because the GnRH-to-gonadotropin cascade outlasts the peptide itself.110 That short half-life motivated longer-acting analogs such as MVT-602/TAK-448, which last around 21 to 22 hours in research. As a peptide, KP-10 is not orally bioavailable; human trials use intravenous bolus or infusion, with subcutaneous injection in some KP-54 protocols.11

What is the evidence by indication?

An important framing point governs everything below: the most mature human RCT evidence in the kisspeptin literature predominantly uses kisspeptin-54, which has a longer half-life and is more practical for sustained dosing. KP-10 itself has robust controlled dose-response physiology data in humans but no Grade-A outcome RCT for a defined therapeutic indication. The grades below are assigned per indication, and the isoform tested is stated explicitly.1

The strongest KP-10-specific data are in the HPG axis. In healthy men, an IV bolus of KP-10 produced a rapid, dose-dependent LH rise: at the optimal 1 microgram/kg dose, LH rose from 4.1 to 12.4 IU/L at 30 minutes (P<0.001, n=6), while higher 3 microgram/kg boluses paradoxically produced less LH. Sustained infusion at 4 micrograms/kg/h raised LH from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L (P<0.001), and a 1.5 microgram/kg/h infusion increased LH pulse frequency (0.7 to 1.0 pulses/h). FSH responses were consistently more modest, and no tachyphylaxis appeared over 22.5 hours of continuous infusion.1 This establishes KP-10 as a potent physiologic HPG-axis stimulant in humans — but as mechanistic/physiology evidence, not an outcome RCT.

The IVF and sexual-function evidence is KP-54's domain. In a dose-finding trial, 53 women undergoing IVF received a single subcutaneous KP-54 injection (1.6 to 12.8 nmol/kg) as the egg-maturation trigger; mature-oocyte rates were 75 to 85%, embryo transfer was achieved in 92%, and there were 10 live births — full data are available at the Journal of Clinical Investigation.3 A subsequent Phase 2 randomized trial in 60 women at high OHSS risk supported efficacy,4 and a further RCT showed a second KP-54 dose improved oocyte maturation.5 Separately, Imperial College RCTs of IV KP-54 (1 nmol/kg/h over 75 minutes) in men with HSDD significantly modulated sexual-processing brain regions versus placebo and augmented penile tumescence by up to 56% more than placebo,6 with parallel modulation of sexual-processing regions in women with HSDD7 and earlier work showing enhanced attraction-pathway brain activity.16 These are well-designed RCTs of surrogate endpoints — promising, but not yet definitive clinical-outcome trials.

What doses appear in the literature?

Reported strictly as information, not a protocol or invitation to self-administer — KP-10 is investigational and unapproved. In men, KP-10 has been given as an IV bolus of 0.01 to 3.0 micrograms/kg, with the peak LH response near 1 microgram/kg and higher boluses giving smaller responses, and as an IV infusion from roughly 1.5 micrograms/kg/h (increasing LH pulse frequency) up to 4 micrograms/kg/h (large LH and testosterone rise), studied to 22.5 hours without tachyphylaxis.1 KP-54, by contrast, has been used as a single subcutaneous bolus of 1.6 to 12.8 nmol/kg for the IVF trigger with oocyte retrieval about 36 hours later,3 and as an IV infusion of 1 nmol/kg/h over 75 minutes in brain-processing work.8 A critical frequency caveat: frequent, twice-daily KP-54 dosing causes tachyphylaxis, so pulsatile or intermittent dosing better preserves responsiveness.9 KP-10 is also chemically unstable in solution, with decomposition half-lives of only a few minutes at body temperature, and there is no FDA-approved formulation or reconstitution standard.10

How safe is Kisspeptin-10?

Tolerability in trials has been good. The KP-10 human dose-response study reported no adverse events, with stable vital signs, blood counts, electrolytes, liver function and renal function across all doses including the 22.5-hour infusion.1 The HSDD RCTs likewise reported KP-54 was well tolerated with no side effects and no significant blood-pressure or heart-rate changes.6 The main pharmacodynamic caveat is tachyphylaxis — frequent dosing desensitizes the axis, with the FSH response nearly abolished by day two of twice-daily KP-54.9 On the regulatory side, the FDA flagged the absence of human immunogenicity data for kisspeptin-10 and the general sterility and purity hazards of compounded injectable peptides.12 A reassuring biological note: KISS1 is a metastasis-suppressor gene and kisspeptin generally inhibits tumor metastasis in models, yet KISS1R is expressed in reproductive and other tissues and the long-term effects of exogenous agonism in humans are simply unstudied — a knowledge gap rather than a documented harm.2 Pregnancy and breastfeeding have not been studied for therapeutic use, and hormone-sensitive conditions warrant caution by mechanism.

What is the FDA and WADA status in 2026?

Kisspeptin-10 is not FDA-approved for any indication, there is no USP/NF monograph, and it is not a component of any approved drug.12 At the October 29, 2024 PCAC meeting, KP-10 was reviewed for the 503A bulk-substances list after being nominated for male secondary hypogonadism and preservation of spermatogenesis with testosterone therapy. The FDA recommended against inclusion and the committee voted not to add it, citing inadequate safety and efficacy evidence and immunogenicity data gaps — so it is not legal to compound under 503A, and it is not on the 503B list.1213 In practice, products are sold labeled "research only, not for human use," outside FDA quality and efficacy oversight, and legitimate human use remains confined to IRB-approved clinical research.12

For athletes the position is unambiguous. Kisspeptin and its agonist analogues are prohibited at all times, in and out of competition, under the 2026 WADA Prohibited List, category S2, subsection S2.2.1 (testosterone-stimulating peptides in males), where they are explicitly grouped with chorionic gonadotrophin, LH, and GnRH and its analogues; the 2026 list took effect January 1, 2026.1415 Any WADA-tested athlete should treat kisspeptin-10 as banned regardless of route or dose.

Bottom line. Kisspeptin is an elegant upstream lever on the reproductive axis whose biology is rock-solid, and KP-10 reliably raises LH and pulse frequency in men. But the leap to a 2026 consumer product is unsupported: there is no Grade-A outcome RCT for any licensed use, the most advanced data use KP-54 not KP-10, the ~4-minute half-life makes practical dosing hard, frequent dosing desensitizes the axis, and the one tested chronic regimen did not restore menses. Graded B for mechanistic and early-clinical promise — unapproved, non-compoundable after the October 2024 PCAC vote, banned in sport, and only legitimately used in IRB research. Regulatory facts here are current as of June 2026 and should be re-verified for any later change.